Male Breast Cancer Clinical Trial
— MALEOfficial title:
A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
Verified date | September 2018 |
Source | German Breast Group |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients (MALE).
Status | Completed |
Enrollment | 56 |
Est. completion date | May 2018 |
Est. primary completion date | May 2018 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 85 Years |
Eligibility |
Inclusion criteria 1. Written informed consent for all study procedures. 2. Complete baseline documentation sent to GBG Forschungs GmbH. 3. Male patients. 4. Age = 18 years. 5. Karnofsky-Index = 60%. 6. Histologically confirmed unilateral or bilateral carcinoma or of the breast at primary diagnosis (enrolment possible in neoadjuvant, adjuvant and metastatic situation). 7: No target lesion necessary for metastatic situation 8. Positive hormone receptor status (e.g. ER and/or PR-receptor positive). 9. Completed staging prior randomisation ( within 8 weeks after diagnose or last therapy (operation, chemotherapy or radiation), minimum: chest X-ray, ultrasound of the liver, bone scan). In case of positive findings, further investigations are required to verify the findings as clinically indicated. 10. Prior chemotherapy is possible. In case of adjuvant treatment: adequate surgical treatment with histological complete resection including axillary lymph nodes if patients are included as adjuvant treatment. A sentinel lymph node biopsy is possible if the sentinel is not involved. 11. Normal cardiac function must be confirmed by ECG within three months prior to randomisation. 12. Laboratory requirements (= 14 days before therapy start): Hematology - Hemoglobin = 9 g/dL, - Leukocytes 4 - 10 x1000/µL, - Thrombocytes 150 - 400 x1000/µL. Hepatic function - ASAT (SGOT) or ALAT (SGPT) = 2x UNL, - Total bilirubin = 2x UNL. Renal function - Serum creatinine = 1.5x UNL, - Creatinine clearance > 30 mL/min (if creatinine is above UNL, according to Cockroft-Gault). - Cholesterol 200 - 240 mg/dL (5.18 - 6.22 mmol/L), - HDL cholesterol > 40 mg/dL (> 1 mmol/L), - LDL cholesterol = 160 mg/dL (= 4 mmol/L). - Prostate specific antigen (PSA) = 2.5 ng/mL. 13. Two serum samples (5 mL) centrally made available. 14. Paraffin tumor tissue block and full blood sample centrally made available (except when the patient does not agree to central biomaterial collection). 15. The patient must be accessible for treatment. Patients can simultaneously be registered in the register study of the University Hospital of Magdeburg. Exclusion Criteria 1. Female patients. 2. Prior endocrine therapy of breast carcinoma. 3. Known or suspected hypersensitivity reaction to the compounds or incorporated substances. 4. No indication for endocrine treatment. 5. Life expectancy of less than six months. 6. International Prostate Symptom Score (IPSS) > 17. 7. Current diagnosis of a Prostate carcinoma. 8. History of prostate cancer within the last five years and regardless the time frame all patients with hormone receptor positive prostate carcinoma who have received endocrine treatment. 9. Concurrent neuronal or cardiac disease, poorly controlled arterial hypertension. 10. Previous thromboembolic event within the last five years (except from thromboembolic events correlated to implanted devices (e.g. port thrombosis) 11. Currently active hepatitis. 12. Disease significantly affecting gastrointestinal function, e.g. malabsorption syndrome, resection of the stomach or small bowel. 13. Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational, not marketed drug within 30 days prior to study entry. 14. Patients who are not able to give informed consent as defined according to AMG. |
Country | Name | City | State |
---|---|---|---|
Germany | Kliniken Essen-Mitte | Essen | Nordrhein-Westfalen |
Lead Sponsor | Collaborator |
---|---|
German Breast Group | Pfizer |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Estradiol blood concentation | To determine the estradiol suppression between the three treatment arms after three months. | 3 months. | |
Secondary | Estradiol blood concentration | To determine the estradiol suppression between the three treatment arms after six months. | 6 months. | |
Secondary | Compliance | To compare the compliance in the three treatment arms. | 6 months. | |
Secondary | Efficacy | To compare the efficacy in terms of overall response (for neoadjuvant and metastatic patients) in the three treatment arms. | 6 months. | |
Secondary | Efficacy perameters | To compare testosterone, dihydrotestosterone (DHT), SHBG, FSH, LH, osteocalcin and CTX in the three treatments arms. | 6 months. | |
Secondary | Safety and side effect parameters | To determine the safety and side effect parameters (at every visit): PSA and hemoglobin. Lipids (total cholesterol, high density lipid cholesterol, low density lipid cholesterol). |
6 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02480933 -
Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens
|
N/A | |
Terminated |
NCT01705340 -
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
Terminated |
NCT01222377 -
Endoscopic Breast Surgery in Treating Patients With Breast Cancer
|
N/A | |
Completed |
NCT00244881 -
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
|
Phase 2 | |
Completed |
NCT00425672 -
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
|
Phase 1/Phase 2 | |
Completed |
NCT00096434 -
Sorafenib in Treating Patients With Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT01217411 -
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
|
Phase 1 | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00791037 -
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00559507 -
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00119262 -
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
|
Phase 2 | |
Terminated |
NCT00095888 -
3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT00098605 -
Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
|
Phase 2 | |
Terminated |
NCT00071942 -
Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
|
Phase 1 | |
Completed |
NCT00068588 -
GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05501704 -
ETHAN - ET for Male BC
|
Phase 2 | |
Completed |
NCT02046421 -
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 1 | |
Completed |
NCT01869764 -
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
|
Phase 2 | |
Completed |
NCT01720602 -
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
|
N/A | |
Terminated |
NCT01931709 -
FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer
|
N/A |